MedeliX
Start asking

Glipizide

Glucotrol-Xl · ATC code A10BB07

Also known as: Glipizid

Key facts
Active substance
Glipizide
Drug class
Sulfonylurea
ATC code
A10BB07
Authorisation
authorised nationally; no central EU authorisation
Information as of
2026-10-29

Key facts

Glipizide is a sulfonylurea glucose-lowering drug. Per the US prescribing information, it is used as an adjunct to diet and exercise in adults with type 2 diabetes.

What it is used for

  • Improvement of glycemic control in adults with type 2 diabetes mellitus, as an adjunct to diet and exercise

Dosing

  • Give approximately 30 minutes before a meal
  • Start with 5 mg before breakfast; geriatric patients or those with liver disease may start on 2.5 mg
  • Titrate in increments of 2.5 to 5 mg several days apart; maximum once-daily dose 15 mg, higher doses divided before meals; maximum total daily dose 40 mg
  • Conservative dosing in elderly, debilitated or malnourished patients and in renal or hepatic impairment
  • Switching from insulin: with 20 units or less daily, insulin may be stopped; above that, reduce insulin by 50%

Contraindications

  • Known hypersensitivity to glipizide
  • Type 1 diabetes mellitus, diabetic ketoacidosis with or without coma

Important warnings

  • Special warning: oral hypoglycemic drugs were associated with increased cardiovascular mortality in the UGDP study
  • Severe hypoglycemia may occur; higher risk with renal or hepatic insufficiency, in elderly or malnourished patients and with adrenal or pituitary insufficiency
  • Hemolytic anemia in G6PD deficiency; use caution and consider an alternative

Side effects

  • Adverse reactions in 11.8% of patients; discontinuation in only 1.5%
  • Gastrointestinal disturbances most common: nausea and diarrhea about one in seventy, constipation and gastralgia about one in one hundred; rarely cholestatic jaundice
  • Allergic skin reactions in about one in seventy; blood dyscrasias reported with sulfonylureas; hypoglycemia

Interactions

  • Enhanced glucose lowering with e.g. NSAIDs, some azoles, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, MAOIs, quinolones and beta-blockers
  • Loss of control with e.g. thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, calcium channel blockers and isoniazid

Pregnancy and breastfeeding

  • If used in pregnancy, discontinue at least one month before the expected delivery date (risk of prolonged neonatal hypoglycemia)
  • Not known whether excreted in human milk; discontinue nursing or the drug

Summary of the official product information, written with AI on 2026-10-29. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.

Full official text →

Common questions – ask Medelix

For patients

Patient information (US)

This product has no separate US patient information.

Authorisation and brand names by country

Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.

Turkey

  • Glucotrol-XlPFİZER PFE İLAÇLARI A.Ş. · 2 register entries

Source: TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, as of 2026-10-16

USA

  • Glucotrol XLRoerig · 1 register entry

Source: U.S. FDA – Drug labels (openFDA/DailyMed), as of 2026-10-29

Brand names in 6 more European countries
Czechia
Minidiab
France
Ozidia
Italy
Minidiab
Poland
Glipizide Bp Galena
Romania
Glucotrol Xl
Spain
Minodiab

EMA – Article 57 product data (EU/EEA), 2026-10-29

Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.

Other substances in the same group

Related calculators

Another question about this substance?

Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.

Sources

  1. U.S. Food and Drug Administration. Glipizide (ANI Pharmaceuticals, Inc.) – Prescribing Information, 2026-07-13. DailyMed (NLM), 2026-10-29. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=252ba4e0-8dc3-43e3-be00-32570dc095bd
  2. TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, 2026-10-16. https://www.titck.gov.tr/dinamikmodul/85
  3. U.S. FDA – Drug labels (openFDA/DailyMed), 2026-10-29. https://dailymed.nlm.nih.gov/dailymed/
  4. Wikidata (CC0): ATC A10BB.

Editorial: Medelix editorial team · last updated 2026-10-29 · How these pages are made · Report an error

Source: U.S. Food and Drug Administration (FDA), prescribing information, via DailyMed (NLM); public domain. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.